MedTrace Logo

PET and MRI Imaging With Scopolamine at the Muscarinic M1 Receptor

NCT06014385 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2025-05-11

No results posted yet for this study

Summary

The purpose of this study is to assess the target occupancy (TO) of scopolamine at M1 Muscarinic Receptors in the brain after single I.V. doses of scopolamine, in healthy control subjects, using the radiotracer \[11C\]EMO (also known as \[11C\]LSN3172176).

Conditions

  • Muscarinic Receptor Occupancy

Interventions

DRUG

Scopolamine

TO will be measured following a 15-minute IV infusion of up to 2 dose levels of scopolamine: 4.0 μg/kg and 2.0 μg/kg

RADIATION

[11C]EMO ([11C]LSN3172176)

A radiotracer specific for imaging M1 receptors. For each PET scan, up to 20 mCi of \[11C\]EMO i.v. will be administered twice, at baseline and post dosing with scopolamine.

Sponsors & Collaborators

  • Janssen Scientific Affairs, LLC

    collaborator INDUSTRY

  • Yale University

    lead OTHER

Principal Investigators

  • David Matuskey, MD · Yale University

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-03-31
Primary Completion
2025-07-01
Completion
2025-07-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06014385 on ClinicalTrials.gov